Press Releases

All Releases
FDA Grants Prostate IDE Approval for AngioDynamics' NanoKnife System
Jun 18, 2013

Pending U.S. Study Parallels European Prostate Efforts

Premier Selects AngioDynamics' BioFlo PICC as a Breakthrough Technology
Jun 12, 2013

BioFlo Technology Highlighted During Fifth Annual Innovation Celebration

AngioDynamics to Present at Jefferies 2013 Global Healthcare Conference
May 28, 2013
ALBANY, N.Y. , May 28, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at Jefferies 2013 Global Healthcare Conference on Monday,
AngioDynamics to Present at UBS Global Healthcare Conference
May 14, 2013
ALBANY, N.Y. , May 14, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the UBS Global Healthcare Conference on Tuesday, May
AngioDynamics Reports Fiscal 2013 Third Quarter Financial Results
Apr 08, 2013
Net sales of $81.6 million GAAP net loss of $0.03 per share; Adjusted (Non-GAAP) net income of $0.08 per share Adjusted EBITDA of $12.7 million , or $0.37 per share; 54% growth over Q3 FY12 Operating cash flow of $10 million versus $6.8 million in prior year ALBANY, N.Y.
AngioDynamics to Report Fiscal 2013 Third Quarter Financial Results and Hold Conference Call on April 8, 2013
Mar 27, 2013
ALBANY, N.Y. , March 27, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2013 third quarter financial
AngioDynamics to Present at Barclays Global Healthcare Conference
Mar 08, 2013
ALBANY, N.Y. , March 8, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the Barclays Global Healthcare Conference on Tuesday,
AngioDynamics Provides Preliminary Fiscal 2013 Third Quarter Results
Mar 07, 2013

Conference Call Scheduled for March 8, 2013 at 8:30 a.m. ET

AngioDynamics to Present at RBC Capital Markets Healthcare Conference
Feb 13, 2013
ALBANY, N.Y. , Feb. 13, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the RBC Capital Markets Global Healthcare Conference
AngioDynamics Completes Acquisition of Microsulis Medical
Feb 01, 2013
ALBANY, N.Y. , Feb. 1, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today said it has completed the previously announced acquisition of certain
AngioDynamics to Acquire Microsulis' Leading Microwave Ablation Technology
Jan 23, 2013
ALBANY, N.Y. , Jan. 23, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it has exercised the option to purchase certain assets of
AngioDynamics to Host Investor and Analyst Day on January 23, 2013
Jan 15, 2013
ALBANY, N.Y. , Jan. 15, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will host an investor and analyst meeting on Wednesday,
AngioDynamics Reports Fiscal 2013 Second Quarter Financial Results
Jan 03, 2013
Pro forma net sales growth of 3% to $87 million Adjusted (Non-GAAP) Net Income of $0.10 per share; GAAP Net Income of $0.06 per share Adjusted EBITDA of $13.8 million ; or $0.39 per share, a 26% YOY increase Operating cash flow of $11.1 million ALBANY, N.Y. , Jan.
AngioDynamics to Present at the J.P. Morgan 2013 Healthcare Conference
Jan 03, 2013
ALBANY, N.Y. , Jan. 3, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology is scheduled to present at the J.P.
AngioDynamics to Report Fiscal 2013 Second Quarter Financial Results and Hold Conference Call on January 3, 2013
Dec 19, 2012
ALBANY, N.Y. , Dec. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2013 second quarter financial
AngioDynamics Appoints George Bourne Chief Technology & Operations Officer
Dec 17, 2012
ALBANY, N.Y. , Dec. 17, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of George W.
Joseph Gersuk to Retire From AngioDynamics; Mark T. Frost Appointed Chief Financial Officer
Nov 19, 2012
ALBANY, N.Y. , Nov. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced Executive Vice President and Chief Financial Officer Joseph
AngioDynamics to Present at the 24th Annual Piper Jaffray Healthcare Conference
Nov 19, 2012
ALBANY, N.Y. , Nov. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference at
AngioDynamics Completes Acquisition of Vortex Medical
Oct 16, 2012
ALBANY, N.Y. , Oct. 16, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has completed the acquisition of Vortex Medical Inc.
AngioDynamics Reports Fiscal 2013 First Quarter Financial Results
Oct 08, 2012
Net sales of $83.4 million GAAP net loss of $0.02 per share; Adjusted (Non-GAAP) net income of $0.10 per share, a YOY 25% increase Integration of Navilyst Medical yielding significant cost savings Vortex Medical acquisition to strengthen peripheral vascular portfolio ALBANY, N.Y. , Oct.
Displaying 141 - 160 of 623

Copyright West LLC. Minimum 15 minutes delayed.